1.0
Cite Score 2025
SJR: 0.129 / SNIP: 0.140
JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
Volume 18, Issue 2 (2026)
3 2026, 18(2): 149-155 |
Back to browse issues page
Request Type:
History
Received: 2026/02/11 | Accepted: 2026/04/1 | Published: 2026/04/20
Received: 2026/02/11 | Accepted: 2026/04/1 | Published: 2026/04/20
How to cite this article
Jasim A, Hamadi H. Cytochrome P450 2C19 Deficiency as the Sole Predictor of Major Adverse Cardiovascular Events in Post-COVID-19 Patients. 3 2026; 18 (2) :149-155
URL: http://ijwph.daneshafarand.org/article-3-85701-en.html
URL: http://ijwph.daneshafarand.org/article-3-85701-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Al-Manara College for Medical Sciences, University of Manara, Maysan, Iraq
Abstract (15 Views)
Aims: Post-COVID-19 syndrome increases the risk of major adverse cardiovascular events (acute myocardial infarction, deep vein thrombosis, ischemic stroke, and pulmonary embolism). We examined whether the cytokine-driven inflammatory milieu after COVID-19 continuously decreases circulating cytochrome P450 2C19 activity and whether this reduction independently predicts MACE risk in these patients.
Materials & Methods: This prospective, single-center, case-control study was conducted at the Maysan Center for Heart Diseases and Surgery, Maysan Health Directorate, Amarah, Maysan Province, Iraq, from October 2022 to November 2024. A total of 210 adult participants were recruited from the outpatient cardiology and post-COVID-19 follow-up clinics of the Maysan Center for Heart Diseases and Surgery and divided into two groups (n=105 per group). Statistical analyses were conducted using SPSS 26 and GraphPad Prism 10.
Findings: Case patients had significantly lower plasma cytochrome P450 2C19 activity than post-COVID-19 controls (0.531±0.114 vs. 0.812±0.071U/L; p<0.001; Cohen’s d=2.98). Cytochrome P450 2C19 activity was negatively correlated with hsCRP (r=0.481; p<0.001), IL-6 (r=0.512; p<0.001), and D-dimer (r=0.443; p<0.001). In ROC analysis, CYP2C19 activity showed excellent discrimination for major adverse cardiovascular events after COVID-19 (area under the curve=0.924; 95% CI: 0.889–0.959; p<0.001). Using an optimal cut-off of 0.6480U/L yielded sensitivity of 86.7% and specificity of 90.5%.
Conclusion: Markedly reduced post–COVID-19 cytochrome P450 2C19 enzymatic activity is a standalone, highly reliable independent biomarker for predicting major adverse cardiac events.
Materials & Methods: This prospective, single-center, case-control study was conducted at the Maysan Center for Heart Diseases and Surgery, Maysan Health Directorate, Amarah, Maysan Province, Iraq, from October 2022 to November 2024. A total of 210 adult participants were recruited from the outpatient cardiology and post-COVID-19 follow-up clinics of the Maysan Center for Heart Diseases and Surgery and divided into two groups (n=105 per group). Statistical analyses were conducted using SPSS 26 and GraphPad Prism 10.
Findings: Case patients had significantly lower plasma cytochrome P450 2C19 activity than post-COVID-19 controls (0.531±0.114 vs. 0.812±0.071U/L; p<0.001; Cohen’s d=2.98). Cytochrome P450 2C19 activity was negatively correlated with hsCRP (r=0.481; p<0.001), IL-6 (r=0.512; p<0.001), and D-dimer (r=0.443; p<0.001). In ROC analysis, CYP2C19 activity showed excellent discrimination for major adverse cardiovascular events after COVID-19 (area under the curve=0.924; 95% CI: 0.889–0.959; p<0.001). Using an optimal cut-off of 0.6480U/L yielded sensitivity of 86.7% and specificity of 90.5%.
Conclusion: Markedly reduced post–COVID-19 cytochrome P450 2C19 enzymatic activity is a standalone, highly reliable independent biomarker for predicting major adverse cardiac events.
Keywords:
References
1. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-90. [Link] [DOI:10.1038/s41591-022-01689-3]
2. Bhatt AS, Bhatt DL, Bhatt DK, Bhatt AB. Cardiovascular complications of COVID-19. J Am Col Cardiol. 2022;79(17):1704-6. [Link]
3. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: Major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-46. [Link] [DOI:10.1038/s41579-022-00846-2]
4. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-15. [Link] [DOI:10.1038/s41591-021-01283-z]
5. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038-44. [Link] [DOI:10.1093/eurheartj/ehaa623]
6. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):360. [Link] [DOI:10.1186/s13054-020-03077-0]
7. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-62. [Link] [DOI:10.1056/NEJMoa0809171]
8. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): Metabolism and biochemical function. Prog Lipid Res. 2004;43(1):55-90. [Link] [DOI:10.1016/S0163-7827(03)00049-3]
9. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285(5431):1276-9. [Link] [DOI:10.1126/science.285.5431.1276]
10. Deng Y, Theken KN, Lee CR. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol. 2010;48(2):331-41. [Link] [DOI:10.1016/j.yjmcc.2009.10.022]
11. Jover R, Bort R, Gómez-Lechón MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: Molecular mechanism and transcription factors involved. FASEB J. 2002;16(13):1799-801. [Link] [DOI:10.1096/fj.02-0195fje]
12. Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006;46:123-49. [Link] [DOI:10.1146/annurev.pharmtox.46.120604.141059]
13. Correia MA, Hollenberg PF. Inhibition of cytochrome P450 enzymes. In: Ortiz De Montellano PR, editor. Cytochrome P450: Structure, mechanism, and biochemistry. Cham: Springer; 2015. p. 177-259. [Link] [DOI:10.1007/978-3-319-12108-6_5]
14. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989;45(4):348-55. [Link] [DOI:10.1038/clpt.1989.40]
15. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics. 1992;2(1):25-31. [Link] [DOI:10.1097/00008571-199202000-00005]
16. Lodhi S, Reddy VP. Environmental dust exposure, oxidative stress, and cardiopulmonary health: Mechanistic insights and global relevance. Environ Res. 2022;214:113758. [Link]
17. Schraufnagel DE. The health effects of ultrafine particles. Exp Mol Med. 2020;52(3):311-7. [Link] [DOI:10.1038/s12276-020-0403-3]
18. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4. [Link] [DOI:10.1001/jama.2013.281053]
19. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction. Am Col Cardiol. 2018;138(20):2231-64. [Link] [DOI:10.1016/j.jacc.2018.08.1038]
20. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther. 1997;282(3):1608-14. [Link] [DOI:10.1016/S0022-3565(24)36947-2]
21. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20(3):153-67. [Link] [DOI:10.2133/dmpk.20.153]
22. Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010;31(18):2197-204. [Link] [DOI:10.1093/eurheartj/ehq251]
23. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-7. [Link] [DOI:10.1056/NEJMoa020233]
24. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-75. [Link] [DOI:10.1056/NEJMoa0808227]
25. Lund LC, Hallas J, Nielsen H, Koch A, Mogensen SH, Brun NC, et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: A Danish population-based cohort study. Lancet Infect Dis. 2021;21(10):1373-82. [Link] [DOI:10.1016/S1473-3099(21)00211-5]
26. Xu M, Bhatt DK, Bhatt DL, Rüsing CJ, Prasad B. Interplay between inflammatory signalling and cytochrome P450-mediated drug metabolism. Drug Metab Dispos. 2021;49(8):641-9. [Link]